Curza
Curza is a small-molecule therapeutics company based in Provo, UT, dedicated to developing novel classes of antibiotics to combat the global threat of antibiotic resistance. With a focus on infectious diseases, Curza has developed several structurally distinct proprietary drugs, including CZ-02, a new class of broad spectrum antibiotics targeting drug-resistant Gram-negative bacteria.
Driven by the rising epidemic of antibiotic resistance, Curza's goal is to address the urgent need for effective antibiotics, as antibiotic resistance contributes to the death of 5,000,000 people annually. Through their innovative ribosomal antibiotics program, Curza aims to develop antibiotics that show both selectivity and potent activity against ESKAPE pathogens, while also focusing on the development of antibiofilm antibiotics to combat biofilm-related infections.
Generated from the website
